Sverige - svenska - Läkemedelsverket (Medical Products Agency)

laurus generics gmbh - metforminhydroklorid - filmdragerad tablett - 500 mg - metforminhydroklorid 500 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

laurus generics gmbh - metforminhydroklorid - filmdragerad tablett - 1000 mg - metforminhydroklorid 1000 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

laurus generics gmbh - metforminhydroklorid - filmdragerad tablett - 850 mg - metforminhydroklorid 850 mg aktiv substans

Europeiska unionen - svenska - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Europeiska unionen - svenska - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Europeiska unionen - svenska - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin hydroklorid - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 och 5. 1 för tillgänglig data på olika kombinationer).

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - metforminhydroklorid; vildagliptin - filmdragerad tablett - 50 mg/850 mg - laktosmonohydrat hjälpämne; metforminhydroklorid 850 mg aktiv substans; vildagliptin 50 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - metforminhydroklorid; vildagliptin - filmdragerad tablett - 50 mg/1000 mg - laktosmonohydrat hjälpämne; vildagliptin 50 mg aktiv substans; metforminhydroklorid 1000 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

merck santé s.a.s. - metforminhydroklorid - filmdragerad tablett - 1000 mg - metforminhydroklorid 1000 mg aktiv substans - metformin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

viatris limited - metforminhydroklorid - filmdragerad tablett - 1000 mg - metforminhydroklorid 1000 mg aktiv substans - metformin